PRG-1820

N/A

Report date: 2025/06/11 10:31:14

Base Information

Drug NamePRG-1820
Drug Alias Nameanti-CD5 CAR T-cell therapy (Shenzhen Pregene Biopharma)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 modulatorsImmunostimulantsT lymphocytes stimulants
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShenzhen Pregene Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Pregene Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A